NASDAQ:AXSM - Axsome Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $89.22
  • Forecasted Upside: 234.04 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.81 (-6.35%)

This chart shows the closing price for AXSM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Axsome Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXSM

Analyst Price Target is $89.22
▲ +234.04% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $89.22, with a high forecast of $180.00 and a low forecast of $34.00. The average price target represents a 234.04% upside from the last price of $26.71.

This chart shows the closing price for AXSM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Axsome Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2021MizuhoLower Price TargetBuy$55.00 ➝ $51.00High
11/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
11/9/2021SVB LeerinkLower Price TargetOutperform$75.00 ➝ $65.00High
9/15/2021HC WainwrightReiterated RatingBuy$180.00Low
8/30/2021HC WainwrightReiterated RatingBuy$225.00 ➝ $180.00Low
8/27/2021William BlairReiterated RatingBuyLow
8/23/2021MizuhoReiterated RatingBuy$55.00High
8/10/2021BTIG ResearchLower Price TargetBuy ➝ Buy$123.00 ➝ $55.00High
8/10/2021SVB LeerinkLower Price TargetPositive ➝ Outperform$115.00 ➝ $75.00High
8/10/2021Truist FinancialLower Price TargetBuy$200.00 ➝ $160.00High
8/10/2021MizuhoLower Price TargetBuy$118.00 ➝ $55.00High
8/10/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$105.00 ➝ $34.00High
7/16/2021William BlairSet Price TargetBuy$56.77High
6/10/2021Berenberg BankInitiated CoverageBuy$112.00High
5/26/2021Morgan StanleyBoost Price TargetOverweight$104.00 ➝ $105.00Medium
5/12/2021BTIG ResearchReiterated RatingBuyLow
4/27/2021HC WainwrightBoost Price TargetBuy$210.00 ➝ $225.00High
3/2/2021MizuhoLower Price TargetBuy$120.00 ➝ $118.00Low
3/2/2021Morgan StanleyBoost Price TargetOverweight$101.00 ➝ $104.00Low
1/8/2021Jefferies Financial GroupInitiated CoverageBuy$129.00Low
12/31/2020UBS GroupReiterated RatingPositiveN/A
12/15/2020MizuhoInitiated CoverageBuy$120.00Low
12/3/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$131.00 ➝ $161.00High
11/9/2020Morgan StanleyLower Price TargetOverweight$102.00 ➝ $101.00Low
10/1/2020William BlairReiterated RatingBuyLow
9/29/2020Bank of AmericaInitiated CoverageUnderperform$66.00High
9/10/2020Morgan StanleyInitiated CoverageOverweight$102.00Low
9/4/2020William BlairReiterated RatingBuyN/A
8/21/2020William BlairReiterated RatingBuyLow
8/10/2020William BlairReiterated RatingBuyMedium
8/6/2020HC WainwrightReiterated RatingBuy$210.00Low
7/14/2020HC WainwrightReiterated RatingBuy$210.00Medium
6/30/2020HC WainwrightReiterated RatingBuy$210.00High
4/28/2020GuggenheimBoost Price TargetIn-Line ➝ Buy$158.00 ➝ $200.00Medium
4/28/2020HC WainwrightBoost Price TargetBuy$200.00 ➝ $210.00Medium
4/27/2020Cantor FitzgeraldBoost Price TargetOverweight$125.00 ➝ $131.00Low
4/27/2020LADENBURG THALM/SH SHBoost Price TargetPositive ➝ Buy$165.00 ➝ $186.00Low
4/27/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$145.00 ➝ $200.00High
4/14/2020CowenInitiated CoverageOutperform$95.00High
4/6/2020William BlairReiterated RatingBuyHigh
4/6/2020HC WainwrightReiterated RatingBuy$200.00High
3/16/2020HC WainwrightReiterated RatingBuy$200.00High
2/24/2020HC WainwrightReiterated RatingBuy$200.00Low
1/28/2020HC WainwrightReiterated RatingBuy$200.00High
1/21/2020HC WainwrightReiterated RatingBuyMedium
1/14/2020LADENBURG THALM/SH SHReiterated RatingBuy$139.00 ➝ $165.00Medium
1/2/2020SunTrust BanksBoost Price TargetBuy$140.00Medium
12/30/2019BTIG ResearchBoost Price TargetBuy$97.00Medium
12/30/2019LADENBURG THALM/SH SHBoost Price TargetBuy$139.00 ➝ $165.00Low
12/30/2019Cantor FitzgeraldReiterated RatingOverweight$104.00 ➝ $125.00Medium
12/24/2019HC WainwrightReiterated RatingBuy$170.00 ➝ $200.00Medium
12/17/2019SunTrust BanksBoost Price TargetBuy$100.00High
12/17/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$97.00High
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$125.00Medium
12/16/2019Cantor FitzgeraldBoost Price TargetOverweight$55.00 ➝ $104.00High
12/4/2019GuggenheimBoost Price Target$65.00 ➝ $48.00High
12/4/2019SunTrust BanksReiterated RatingBuy ➝ Positive$60.00High
12/4/2019BTIG ResearchReiterated RatingBuy ➝ Positive$48.00Medium
12/3/2019Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$45.00 ➝ $55.00High
11/26/2019Cantor FitzgeraldReiterated RatingBuy$45.00High
10/17/2019HC WainwrightReiterated RatingBuy$30.00High
10/16/2019GuggenheimInitiated CoverageBuy$48.00High
9/18/2019William BlairInitiated CoverageOutperform$48.00Low
6/24/2019HC WainwrightSet Price TargetBuy$30.00Low
5/28/2019Cantor FitzgeraldReiterated RatingOverweight$25.00 ➝ $35.00Low
5/28/2019SunTrust BanksInitiated CoverageBuy ➝ BuyLow
5/23/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $30.00High
4/15/2019HC WainwrightReiterated RatingBuy ➝ Average$18.00 ➝ $23.00High
4/8/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00Medium
3/28/2019BTIG ResearchBoost Price TargetBuy$25.00Low
3/26/2019HC WainwrightSet Price TargetBuy$18.00High
3/21/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $25.00High
3/15/2019HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $18.00High
3/15/2019Cantor FitzgeraldBoost Price TargetOverweight$13.00 ➝ $16.00High
3/5/2019HC WainwrightSet Price TargetBuy$15.00High
1/31/2019HC WainwrightReiterated RatingBuy$15.00Low
1/14/2019HC WainwrightReiterated RatingBuy$15.00Low
1/8/2019BTIG ResearchBoost Price TargetBuy$20.00High
1/7/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$34.00 ➝ $45.00High
1/7/2019HC WainwrightBoost Price TargetBuy$15.00High
12/10/2018Cantor FitzgeraldSet Price TargetBuy$16.00High
12/5/2018HC WainwrightReiterated RatingBuy$10.00High
11/15/2018Cantor FitzgeraldInitiated CoverageOverweight$16.00High
10/24/2018HC WainwrightSet Price TargetBuy$10.00Low
10/17/2018LADENBURG THALM/SH SHSet Price TargetBuy$34.00 ➝ $5.00High
10/9/2018HC WainwrightSet Price TargetBuy$10.00High
8/21/2018HC WainwrightReiterated RatingBuy$10.00Low
6/7/2018HC WainwrightInitiated CoverageBuy$10.00High
4/29/2018BTIG ResearchReiterated RatingBuy$16.00High
12/1/2017Cantor FitzgeraldSet Price TargetBuy$13.00Low
7/26/2017LADENBURG THALM/SH SHReiterated RatingBuy$28.00 ➝ $31.00High
6/20/2017AegisReiterated RatingBuy$20.00High
5/25/2017AegisReiterated RatingBuy$20.00Medium
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00High
3/21/2017AegisReiterated RatingBuyHigh
3/8/2017Cantor FitzgeraldSet Price TargetBuy$13.00Low
2/14/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/A
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 6 very negative mentions
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 7 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment


  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Axsome Therapeutics logo
Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More

Today's Range

Now: $26.71
Low: $26.61
High: $29.27

50 Day Range

MA: $34.49
Low: $26.71
High: $39.26

52 Week Range

Now: $26.71
Low: $19.38
High: $78.00


529,951 shs

Average Volume

580,663 shs

Market Capitalization

$1.01 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Axsome Therapeutics?

The following Wall Street analysts have issued reports on Axsome Therapeutics in the last year: Berenberg Bank, BTIG Research, Cantor Fitzgerald, HC Wainwright, Mizuho, Morgan Stanley, SVB Leerink LLC, Truist Financial Co., William Blair, and Zacks Investment Research.
View the latest analyst ratings for AXSM.

What is the current price target for Axsome Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Axsome Therapeutics in the last year. Their average twelve-month price target is $89.22, suggesting a possible upside of 212.8%. HC Wainwright has the highest price target set, predicting AXSM will reach $180.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $34.00 for Axsome Therapeutics in the next year.
View the latest price targets for AXSM.

What is the current consensus analyst rating for Axsome Therapeutics?

Axsome Therapeutics currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXSM will outperform the market and that investors should add to their positions of Axsome Therapeutics.
View the latest ratings for AXSM.

What other companies compete with Axsome Therapeutics?

How do I contact Axsome Therapeutics' investor relations team?

Axsome Therapeutics' physical mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company's listed phone number is (212) 332-3241. The official website for Axsome Therapeutics is